Expiration date: 09/2026

Release form and composition:

Tablets almost white, round, flat, beveled edge, scored on one side and the stamp VASOBRAL on the other.

1 tablet contains:

alpha dihydroergocryptine mesylate 4 mg

caffeine 40 mg

Excipients: lactose monohydrate, cellulose microcrystalline, magnesium stearate, silica colloidal anhydrous.

10 PCs. - blisters (1) - packs of cardboard.

10 PCs. - blisters (3) - packs cardboard.

Solution for the reception inside the bright, colorless or pale yellow, with a smell of alcohol.

1 ml contains:

alpha dihydroergocryptine mesylate 1 mg

caffeine 10 mg

Auxiliary substances: citric acid, ethanol, glycerol, purified water.

50 ml - vials dark glass (1) complete with dosing syringe packs cardboard.

Pharmacological action:

Part was Vasobral alpha dihydroergocryptine - digidrirovannoe derived ergot - blocks apha1 and apha2-adrenergic receptors of smooth muscle cells of blood vessels. It has a stimulating effect on dopamine and serotonin receptors in the Central nervous system.

In applying the drug reduces the aggregation of platelets and red blood cells, decreases vascular permeability, improves blood circulation and metabolic processes in the brain, increases resistance brain tissue to hypoxia.

Caffeine has a stimulating effect on the Central nervous system, primarily the cerebral cortex, the respiratory and vasomotor centers. Enhances mental and physical performance, reduces fatigue.

Pharmacokinetics:

Suction

Absorption alpha dihydroergocryptine from the intestine is accelerated in the presence of caffeine. Cmax after intake of 8 mg of alpha-dihydroergocryptine is achieved in 30 minutes and is 227 PG/ml.

Distribution

Digidrirovannye ergot alkaloids are found in small quantities in breast milk.

Excretion

T1/2 alpha dihydroergocryptine is less than 2 hours write mainly jelchew.

Indications:

• mental decline, attention disorders, memory and orientation in space related to age-related changes
  
• cerebrovascular insufficiency (including as a result of cerebral atherosclerosis)
  
• residual effects after cerebrovascular accident
  
• prevention of migraine
  
• cochleo-vestibular disorders (dizziness, tinnitus, hypacusia) ischemic
  
• Meniere's disease
  
• retinopathy (diabetic and hypertensive)
  
• human peripheral blood circulation (syndrome and Raynaud's disease)
  
• venous insufficiency.
  

Dosing regimen:

1/2-1 tab. or 2-4 ml of solution 2 times/day. Duration of treatment is 2-3 months, if necessary, possibly re courses.

The drug should be taken during meals with a small amount of water. Solution before use should be diluted with a little water.

Side effects:

From the digestive system: rarely - nausea, epigastric pain, dyspepsia.

CNS: rarely (less than 1%) - dizziness, headache, agitation.

From the side of cardiovascular system: very rare (less than 0.1%) - tachycardia, hypotension.

Allergic reactions: very rare (less than 0.1%) - pruritus, rash.

Contraindications:

• increased individual sensitivity to product components.
  

Pregnancy and lactation:

Security application Vasobral during pregnancy has not been proven.

Appointment Vasobral nursing mothers may lead to reduced lactation.

Special instructions:

In appointing the drug to patients with arterial hypertension does not exclude the need for the use of antihypertensive drugs.

Caffeine, a part of the drug was Vasobral can cause sleep disturbance, tachycardia.

Overdose:

Symptoms: strengthening described side effects.

Treatment: if necessary, symptomatic therapy.

Drug interactions:

While the application has Vasobral and antihypertensive drugs may develop hypotension and fainting.

Caffeine, a part of the drug was Vasobral reduces the effect of hypnotics.

Terms and conditions of storage:

List B. the Drug should be stored at normal humidity and at a temperature of from 15° to 25°C.

The shelf life of the tablets - 4-year shelf life solution for the reception inside - 3 years. Do not use after the expiry date stated on the package.